Dr. Yang Wenqing, CSO, Invited to Serve on the Scientific Committee for the 2023 International Conference on Oncology and Cancer Research and Delivers a Keynote Speech
2023-06-22
Dr. Yang Wenqing, founder and CSO of ClinBridge Bio, was invited to organize and delivered a keynote speech at the International Conference on Cancer and Oncology Research held on June 19-20, 2023, in Rome, Italy.
The International Conference on Cancer and Oncology Research is one of the most important global events in the field of oncology, attracting top scientists, biopharmaceutical companies, doctors, and researchers from around the world. Dr. Yang’s invitation to join the organizing committee and deliver a keynote reflects the oncological academic community's recognition of his outstanding contributions to cancer translational research. It also honors ClinBridge Bio and affirms the company's level of scientific and technological research.
As a member of the scientific committee for this conference, Dr. Yang contributed significantly to the event's preparation. He delivered a keynote titled “Combining Antiangiogenic and Immunotherapeutic Approaches to Achieve Synergistic Efficacy in Cancer Treatment.” As the CSO and founder of ClinBridge Bio, Dr. Yang has extensive experience in oncology and cancer research. His presentation covered the latest oncological breakthroughs, innovative treatment methods, and clinical research results, attracting significant attention and sparking lively discussions and positive feedback.
ClinBridge Biotech has been heavily investing in the fields of oncology and tumor immunology, aiming to provide differentiated one-stop drug-likeness evaluation services to biopharmaceutical development enterprises. Dr. Yang’s presentation highlighted the company's excellence in scientific research and clinical practice, enhancing industry recognition of the company.
Dr. Yang also actively participated in several collaborative projects, working together with international peers to address key challenges in the field of oncology. His contributions are highly praised within the international oncological community and have solidified ClinBridge Bio’s leading position in oncology. Under Dr. Yang's leadership, ClinBridge Biotech will continue its outstanding work in oncology and cancer research, driving the development of antitumor drug-likeness research and providing better one-stop solutions to accelerate the drug approval process for pharmaceutical companies.
联科
Official Public Number
Copyright©2023 Nanjing Yunqiao Purui Biotechnology Co., Ltd.
